APA (7th ed.) Citation

Robinson, J., Farnier, M., Kastelein, J., Roth, E., Taskinen, M., Colhoun, H., . . . Cannon, C. (2016). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis (00219150), 252, e231. https://doi.org/10.1016/j.atherosclerosis.2016.07.219

Chicago Style (17th ed.) Citation

Robinson, J.G, et al. "Pharmacodynamic Relationship Between PCSK9, Alirocumab, and LDL-C Lowering in Four Phase 3 Odyssey Trials With/without Statin Background." Atherosclerosis (00219150) 252 (2016): e231. https://doi.org/10.1016/j.atherosclerosis.2016.07.219.

MLA (9th ed.) Citation

Robinson, J.G, et al. "Pharmacodynamic Relationship Between PCSK9, Alirocumab, and LDL-C Lowering in Four Phase 3 Odyssey Trials With/without Statin Background." Atherosclerosis (00219150), vol. 252, 2016, p. e231, https://doi.org/10.1016/j.atherosclerosis.2016.07.219.